Reinterpreting TRIPS in the life sciences
The TRIPS agreement from 1994 forms a central legal framework for the development of a global IPR regime through a de minimis protection of IPR. The agreement contains both features of harmonization, flexibilities and basic principles that affect the development of the IP agenda worldwide. Human ingenuity, consensus-based international politics, national and economic interests present substantial challenges to the application and interpretation of these features of the TRIPS agreement and are of significant importance to the continuous development of the life science sector.
In a series of webinars in 2017 and 2018 international experts set focus on the TRIPS agreement and the life sciences. The aim of the webinars was to bring together scholars, industry and practitioners in constructive dialogue on pressing legal issues arising at this intersection IPR and innovation in this field.
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) supported and co-funded the project.